US2012295843A1PendingUtilityA1

Combination therapy for the treatment of hcv infection

43
Assignee: KWONG ANNPriority: May 4, 2007Filed: Aug 1, 2012Published: Nov 22, 2012
Est. expiryMay 4, 2027(~0.8 yrs left)· nominal 20-yr term from priority
Inventors:Ann Dak-Yee KwongNagraj ManiYi ZhouChao Lin
A61P 31/12A61P 43/00A61P 31/14A61K 31/497A61P 1/16A61K 45/06A61K 31/7068
43
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to therapeutic combinations comprising a protease inhibitor and a polymerase inhibitor for the treatment of HCV. The present invention also relates to therapeutic combinations comprising VX-950 and a polymerase inhibitor. Also within the scope of the invention are methods using the therapeutic combinations of the present invention for treating HCV infection or alleviating one or more symptoms thereof in a patient. The present invention also provides kits comprising the combinations of the present invention.

Claims

exact text as granted — not AI-modified
1 . A therapeutic combination comprising VX-950 and a polymerase inhibitor selected from the group consisting of R7128 and IDX184. 
     
     
         2 . The therapeutic combination of  claim 1 , wherein the polymerase inhibitor is R7128. 
     
     
         3 . The therapeutic combination of  claim 1 , wherein the polymerase inhibitor is IDX184. 
     
     
         4 . A kit comprising: (i) a therapeutic combination of  claim 1 ; and (ii) instructions for utilizing said combination. 
     
     
         5 . A method of treating HCV infection, or alleviating one or more symptoms thereof in a patient, comprising administering VX-950 in combination with a polymerase inhibitor selected from the group consisting of R7128 and IDX184. 
     
     
         6 . The method of  claim 5 , wherein the polymerase inhibitor is R7128. 
     
     
         7 . The method of  claim 5 , wherein the polymerase inhibitor is IDX184. 
     
     
         8 . The method of  claim 5 , wherein the HCV infection is genotype 1. 
     
     
         9 . The method of  claim 5 , wherein said patient is a treatment naive patient. 
     
     
         10 . The method of  claim 5 , wherein said patient is non-responsive to interferon monotherapy. 
     
     
         11 . The method of  claim 5 , wherein said patient is non-responsive to a combination therapy using ribavirin and an interferon. 
     
     
         12 . The method of  claim 5 , wherein the patient is infected by an HCV variant.

Join the waitlist — get patent alerts

Track US2012295843A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.